Screener
G&A at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Praxis Precision Medicines, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 8:32 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001689548-26-000083
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating expenses: | ||||
| Research and development | $69,416 | $63,006 | $147,403 | $123,812 |
| General and administrative | 27,488 | 13,061 | 55,361 | 26,983 |
| Total operating expenses | 96,904 | 76,067 | 202,764 | 150,795 |
| Loss from operations | (96,904) | (76,067) | (202,764) | (150,795) |
| Other income: | ||||
| Other income, net | 13,184 | 4,940 | 26,483 | 10,372 |
| Total other income | 13,184 | 4,940 | 26,483 | 10,372 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Praxis Precision Medicines, Inc.'s G&A?
- Praxis Precision Medicines, Inc. (PRAX) reported G&A of $27.49M in Q2 2026.
- How has Praxis Precision Medicines, Inc.'s G&A changed year-over-year?
- Praxis Precision Medicines, Inc.'s G&A increased by 110.5% year-over-year, from $13.06M to $27.49M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s G&A?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s G&A has grown at a 5.8% compound annual growth rate (CAGR), from $47.08M to $59.08M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Praxis Precision Medicines, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude